Edition:
India

Jubilant Life Sciences Ltd (JULS.NS)

JULS.NS on National Stock Exchange of India

743.35INR
22 Jun 2018
Change (% chg)

Rs6.90 (+0.94%)
Prev Close
Rs736.45
Open
Rs737.00
Day's High
Rs754.90
Day's Low
Rs734.15
Volume
419,456
Avg. Vol
729,159
52-wk High
Rs1,039.00
52-wk Low
Rs600.00

Chart for

About

Jubilant Life Sciences Limited is an India-based pharmaceutical and life sciences company. The Company is engaged in providing basic organic chemicals. The Company's segments include Pharmaceuticals and Life Sciences Ingredients. The Pharmaceuticals segment consists of generics, including active pharmaceuticals ingredients... (more)

Overall

Beta: 1.54
Market Cap(Mil.): Rs105,929.90
Shares Outstanding(Mil.): 159.28
Dividend: 3.00
Yield (%): 0.45

Financials

  JULS.NS Industry Sector
P/E (TTM): 18.47 30.95 32.74
EPS (TTM): 36.00 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.08

BRIEF-Jubilant Life Sciences Says Unit Got ANDA Approval For Amantadine Hydrochloride Tablets​

* UNIT, JUBILANT PHARMA GETS ANDA FINAL APPROVAL FOR AMANTADINE HYDROCHLORIDE TABLETS, GENERIC VERSION OF SYMMETREL OF ENDO​ Source text: http://bit.ly/2EtLooJ Further company coverage:

09 Feb 2018

BRIEF-Jubilant Life Sciences Says Unit Got ANDA Approval For Clonidine Hydrochloride Extended-Release Tablets‍​

* JUBILANT PHARMA GOT ANDA APPROVAL FOR CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS‍​ Source text: http://bit.ly/2Gt6DoZ Further company coverage:

30 Jan 2018

BRIEF-India's Jubilant Life Sciences Issues Commercial Papers Worth 900 Mln Rupees

* ISSUED COMMERCIAL PAPERS WORTH 900 MILLION RUPEES Source text - http://bit.ly/2mElAvi Further company coverage:

17 Jan 2018

BRIEF-India's Jubilant Life Sciences Dec Qtr Consol Profit Up 78 Pct

* DEC QUARTER CONSOL NET PROFIT 2.13 BILLION RUPEES VERSUS PROFIT OF 1.19 BILLION RUPEES LAST YEAR

17 Jan 2018

BRIEF-Jubilant Life Sciences Unit Gets sNDA Approval For New Indications From USFDA For Draximage DTPA

* SAYS UNIT GETS SNDA APPROVAL FOR NEW INDICATIONS FROM USFDA FOR DRAXIMAGE® DTPA Source text for Eikon: Further company coverage:

28 Dec 2017

Earnings vs. Estimates